Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies

Grenader, Tal; Nash, Stephen; Plotkin, Yevgeni; Furuse, Junji; Mizuno, Nobumasa; Okusaka, Takuji; Wasan, Harpreet; Valle, Juan W.; Bridgewater, John

doi:10.1093/annonc/mdv253

Cited by 71 publications

(64 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…investigated a total of 162 patients with metastatic colorectal cancer who received palliative chemotherapy and reported that patients with pretreatment NLR values of > 5 that decreased to ≤5 before the second chemotherapy cycle showed a significantly longer progression-free survival and a trend towards longer OS compared with patients with a persistent NLR of > 5. Data in patients with oesophageal and biliary cancer have also suggested an association between the NLR and response to cisplatin-based chemotherapy [38, 39]. These results indicated that the NLR was predictive for the prognosis and response to chemotherapy regardless of tumour origin.…”

Section: Discussionmentioning

confidence: 94%

The Neutrophil to Lymphocyte Ratio May Predict Benefit from Chemotherapy in Lung Cancer

Liu

Jin

Zhang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: The objectives of this study were to evaluate the impact of the neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) on overall survival (OS) and to explore the value of changes in the NLR and PLR with treatment as a response indicator. Methods: A total of 934 patients were eligible for retrospective analysis between 2008 and 2014. The pretreatment and post-treatment PLR and NLR in all patients were calculated based on complete blood counts. Univariate and multivariate Cox regression analyses were performed to determine the associations of the PLR and NLR with OS. Results: The pretreatment NLR and PLR were correlated with different disease status and response to chemotherapy. Patients with lower NLR and PLR had a significantly better complete response (CR) rate to chemotherapy versus those with a higher NLR and PLR (p< 0.001). The NLR and PLR were sustained in patients who obtained a CR compared with moderate or poor response patients. The lower NLR of pretreatment was independently associated with a favourable prognosis in whole patients with lung cancer (HR: 0.69, 95% CI, 0.55-0.85, p< 0.001). In the patients under control after chemotherapy, the NLR of post-chemotherapy had a greater impact on survival, and the low NLR level maintained during chemotherapy was identified a predictor for favourable survival. PLR was not an independent prognostic indicator in the whole cohort or any subgroups. Conclusion: Our results suggested that NLR was well-connected with outcomes and response to chemotherapy in patients with lung cancer. As a response indicator, NLR may predict benefit from chemotherapy and improve patient selection.

show abstract

Section: Discussionmentioning

confidence: 94%

The Neutrophil to Lymphocyte Ratio May Predict Benefit from Chemotherapy in Lung Cancer

Liu

Jin

Zhang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…26,27 These might partially explain why an elevated NLR is associated with poor survival. Recent clinical studies revealed that dNLR was associated with chemotherapy response 10,28 and prognosis in many advanced cancers, such as metastatic melanoma, 8 metastatic castration-resistant prostate cancer, 9 advanced biliary cancer, 10 and advanced colorectal cancer. 29 The dNLR is composed of WBCs and neutrophils; this parameter has been proposed as an alternative to NLR for studies where only WBCs and neutrophils have been recorded.…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of pretreatment inflammatory biomarkers in advanced lung adenocarcinoma patients receiving first-line pemetrexed/platinum doublet

et al. 2017

View full text Add to dashboard Cite

Inflammation is a new hallmark feature of cancer initiation and progression. We aimed to investigate the association between inflammatory response biomarkers and progression-free survival and overall survival in advanced lung adenocarcinoma patients treated with first-line pemetrexed and platinum doublet chemotherapy. Patients hospitalized between April 2012 and March 2015 were enrolled and eliminated according to the inclusion and exclusion criteria. The pretreatment neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, derived neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio were calculated. Besides the well-established clinical prognostic factors, the prognostic values of the four markers were evaluated by the Kaplan-Meier method and Cox's proportional hazards regression model. A total of 78 patients were enrolled in this study. Elevated neutrophil-to-lymphocyte ratio and derived neutrophil-to-lymphocyte ratio were correlated with poor treatment response ( p = 0.014, 0.012, respectively). A high pretreatment neutrophil-to-lymphocyte ratio, derived neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio, as well as low lymphocyte-to-monocyte ratio, were associated with worse progression-free survival and overall survival. Multivariate analysis revealed that high neutrophil-to-lymphocyte ratio (hazard ratio = 2.056; 95% confidence interval, 1.281-3.299; p = 0.003) and ≥3 metastasis organs (hazard ratio = 1.989; 95% confidence interval, 1.069-3.702; p = 0.030) were independent prognostic factors for progression-free survival. Meanwhile, high neutrophil-to-lymphocyte ratio (hazard ratio = 5.540; 95% confidence interval, 2.974-10.321; p < 0.001) and habitual smoking (hazard ratio = 2.806; 95% confidence interval, 1.509-5.221; p = 0.001) were independent prognostic factors for overall survival. In conclusion, Pretreatment neutrophil-to-lymphocyte ratio was an independent prognostic factor for advanced lung adenocarcinoma patients treated with first-line pemetrexed/platinum doublet chemotherapy. Elevated pretreatment derived neutrophil-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio might be potential biomarkers for poorer responses to chemotherapy. To verify these findings, larger well-designed prospective studies are needed.

show abstract

“…[9][10][11] In particular, the neutrophil to lymphocyte ratio (NLR), which is considered as a biomarker of SIR, has emerged as an independent prognostic factor for biliary tract cancer in operable patients and in advanced disease patients undergoing adjuvant therapy. 12,13 The lymphocyte to monocyte ratio (LMR) is another biomarker of SIR, with a combination of lymphocyte count and monocyte count. The LMR as a prognostic factor for patients with colorectal cancer and hepatocellular carcinoma was recently investigated in a number of studies.…”

Section: Introductionmentioning

confidence: 99%

Lymphocyte to Monocyte Ratio Predicts Resectability and Early Recurrence of Bismuth-Corlette Type IV Hilar Cholangiocarcinoma

Peng

et al. 2020

Journal of Gastrointestinal Surgery

View full text Add to dashboard Cite

Background The objective of our research was to investigate the value of the lymphocyte to monocyte ratio (LMR) and its dynamic changes (LMRc) in predicting tumor resectability and early recurrence of radiologically resectable type IV hilar cholangiocarcinoma (HC). Methods A total of 411 patients with radiologically resectable type IV HC were included. Data on their clinicopathologic characteristics, perioperative features, and survival outcomes were analyzed. Receiver operating characteristic (ROC) analysis was conducted to assess the ability of preoperative LMR (pre-LMR) to predict tumor resectability, and the ability of postoperative LMR (post-LMR) to discriminate between early and late recurrence. Survival curves were calculated using the Kaplan-Meier estimate. Univariate and multivariate logistic regression models were used to identify factors associated with resectability and early recurrence. Results Of 411 patients with potentially curative type IV HC, 254 underwent curative surgery. The optimal cutoff value of pre-LMR as an indicator of resectability was 3.67, and the optimal cutoff value of post-LMR for detecting early recurrence was 4.10. In the multivariate logistic regression model, CA19-9 > 200 U/mL, pre-LMR ≤ 3.67, and tumor size > 3 cm were found to be independent risk factors for poor resectability. Moreover, multivariate analysis showed that LMRc, resection margin, AJCC N stage, and lymphovascular invasion were independent risk factors associated with early recurrence. Discussion Pre-LMR is a valuable indicator of resectability and LMRc is a valuable predictor of early recurrence in patients with curative type IV HC.

show abstract

Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies

Cited by 71 publications

References 20 publications

The Neutrophil to Lymphocyte Ratio May Predict Benefit from Chemotherapy in Lung Cancer

The Neutrophil to Lymphocyte Ratio May Predict Benefit from Chemotherapy in Lung Cancer

Prognostic value of pretreatment inflammatory biomarkers in advanced lung adenocarcinoma patients receiving first-line pemetrexed/platinum doublet

Lymphocyte to Monocyte Ratio Predicts Resectability and Early Recurrence of Bismuth-Corlette Type IV Hilar Cholangiocarcinoma

Contact Info

Product

Resources

About